Back Our latest news News selection Discover below our latest news and publications related to our oncology compounds and antibiotics. Press releases April 4, 2024 Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego Read more March 7, 2024 Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors Read more January 8, 2024 Debiopharm Extends SunRock Biopharma Partnership for Antibody-Drug Conjugates Targeting HER3 in EGFR Mutated Cancers Read more All Press Releases Publications April 8, 2024 Anti-Tumor Activity of Debio 0123 in Combination with Sacituzumab Govitecan in Preclinical Models of Breast Cancer Read more April 8, 2024 A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a… Read more April 8, 2024 Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase… Read more All Publications About us Partnering with us Product focus Digital Health Our latest news Pipeline